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Abstract
PARAT, a new European Society of Endocrinology program, aims to identify unmet scientific and educational needs 
of parathyroid disorders, such as primary hyperparathyroidism (PHPT), including parathyroid cancer (PC), and 
hypoparathyroidism (HypoPT). The discussions and consensus statements from the first PARAT workshop (September 
2018) are reviewed. PHPT has a high prevalence in Western communities, yet evidence is sparse concerning the 
natural history and whether morbidity and long-term outcomes are related to hypercalcemia or plasma PTH 
concentrations or both. Cardiovascular mortality and prevalence of low energy fractures are increased, whereas 
quality of life is decreased, although their reversibility by treatment of PHPT has not been convincingly demonstrated. 
PC is a rare cause of PHPT, with increasing incidence, and international collaborative studies are required to advance 
knowledge of the genetic mechanisms, biomarkers for disease activity and optimal treatments. For example, ~20% 
of PCs demonstrate high mutational burden, and identifying targetable DNA variations, gene amplifications and gene 
fusions may facilitate personalized care, such as different forms of immunotherapy or targeted therapy. HypoPT, a 
designated orphan disease, is associated with a high risk of symptoms and complications. Most cases are secondary 
to neck surgery. However, there is a need to better understand the relation between disease biomarkers and 
intellectual function and to establish the role of PTH in target tissues, as these may facilitate the appropriate use of 
PTH substitution therapy. Management of parathyroid disorders is challenging, and PARAT has highlighted the need 
for international transdisciplinary scientific and educational studies in advancing in this field.
Introduction
Disorders in the parathyroid glands spans a huge variety 
of clinical important diseases, some with a very high 
prevalence as in primary hyperparathyroidism (PHPT) 
among postmenopausal women (1, 2, 3, 4), some orphan 
like chronic hypoparathyroidism in adults (HypoPT) 
(5, 6), with increasing awareness due to new treatment 
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algorithms (7). Parathyroid carcinomas (PC) are extremely 
rare, but might potentially be underdiagnosed (8, 9, 
10). By far most of parathyroid diseases are sporadic as 
most cases of PHPT, some are part of well-known genetic 
conditions. As such, PHPT is linked to the multiple 
endocrine neoplasia (MEN) syndromes (11), and familial 
hypocalciuric hypercalcemia (FHH) ) is a well-described, 
rare autosomal dominant inherited condition most often 
due to a loss-of-function mutation in the calcium sensor 
and partner proteins (12, 13). Thus, parathyroid disorders 
are heterogeneous conditions with the organs (the glands) 
in common and with clinical awareness and interest often 
reflecting new developments in diagnostic procedures or 
treatment possibilities.
The European Society of Endocrinology (ESE) recently 
established a new program focusing on parathyroid 
disorders – the PARAT program – aiming to identify unmet 
scientific and educational needs in parathyroid diseases. 
The first workshop in Santpoort, The Netherlands in 
September 2018 invited European Top-experts within the 
three main topics, PC, PHPT and HypoPT, based on State 
of the Art Presentations by international experts followed 
by break-out sessions to identify the needs in each area 
and a further discussion in plenum on prioritizing the way 
forward in a 2- to 4-year perspective. The aim of this review 
is to summarize and discuss the recent achievements on 
these three defined topics.
Parathyroid carcinoma
PC is one of the most rare known malignancies and 
accounts for less than 1% of PHPT. Reports from the 
United States, Australia and Finland indicate increasing 
incidences (8, 9, 10). Preoperatively, PC cannot be 
distinguished from benign causes of PHPT, as no disease-
specific markers are available. PC should be suspected in 
patients with severe PTH-dependent hypercalcemia or its 
complications (14), but may be overlooked because it is so 
rare. PC is rather aggressive with a high recurrence rate in 
more than 50% of the cases and the 5-year survival rate in 
patients with metastatic disease is less than 50% (15, 16, 
17). Patients suspected to have PC should have primary 
radical en bloc surgery, performed by an experienced 
surgeon (18), as this is the only treatment that can ensure 
cure. Diagnosis is confirmed by histopathology, which 
also is demanding. Therefore, some patients are correctly 
diagnosed only because of persistent disease after surgery 
or later recurrent/metastatic disease. Histopathology 
should always be performed by an expert parathyroid 
pathologist in a standardized fashion. A main challenge is 
to distinguish PC from an atypical parathyroid adenoma. 
PC is usually sporadic, but may be part of familial 
syndromes such as hyperparathyroidism-jaw tumour 
syndrome (HPT-JT), isolated familial hyperparathyroidism 
(FIHP) and, rarely, MEN1 or MEN2A (18, 19). CDC73 
germline mutations cause HPT-JT and, in 20–40% of the 
cases sporadic PC. In contrast to parathyroid adenomas, 
a majority of PCs are characterized by somatic CDC73 
mutations (20, 21). CDC73 is a tumour suppressor gene 
that encodes parafibromin. In PC, vascular tumour 
invasion and loss of parafibromin expression associate 
with more aggressive behavior and impaired patient 
survival (10, 18, 22). Genetic testing should be offered 
to all patients with PC and when mutation positive, also 
first-degree relatives should be screened. For patients 
with inoperable disease, treatment options are limited. 
Treatment of hypercalcemia is crucial; however, no 
evidence-based disease-specific treatment exist. Given the 
rarity of PC, a collaborative approach is needed in order to 
develop novel diagnostic markers and targeted drugs, and 
hopefully improve outcomes.
Preoperative diagnosis of parathyroid carcinoma
The diagnosis of PC is challenging due to the lack 
of reliable clinical diagnostic criteria and is in the 
majority of cases made postoperatively by histological 
examination. Local invasion of surrounding structures 
(trachea, inferior laryngeal nerve, strap muscles) and 
the occurrence of distant or lymph node metastases 
are the only unequivocal criteria of malignancy. The 
latter, however, usually develop late during follow-up. 
Patients who present with a palpable mass, a serum 
calcium level higher than 3.5 mmol/L and markedly 
elevated PTH levels, severe renal and/or bone disease 
involvement and/or laryngeal nerve palsy should be 
suspected of harboring PC (18). Very rarely however, PC 
is nonfunctioning, that is patients have normal levels of 
plasma calcium and PTH (23).
Currently, no standard imaging studies are able 
to distinguish PC from a benign parathyroid lesion. 
Nonetheless, some ultrasound (US) features may raise 
the suspicion for PC, namely a large (i.e. >3 cm large) 
lobulated hypoechoic/heterogeneous parathyroid gland, 
with irregular borders, thick capsule, suspicious vascularity 
and calcifications (24) (Fig.  1). However, these features 
may also be seen in benign tumors (25). Conversely, Hara 
et al. observed that the depth/width ratio of the lesion >1 
suggest a PC, while <1 a benign tumor (25). Occasionally, 
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the infiltration into surrounding tissues and cervical 
lymph node enlargement can be identified (or suspected). 
99mTc-sestamibi (MIBI) scan is routinely used for imaging 
abnormal/ectopic parathyroid lesion but cannot predict 
malignancy. When there is a strong suspicion for PC 
higher resolution studies can be useful, namely contrast 
computed tomography (CT), including 4-dimensional 
computed tomography (4DCT), magnetic resonance 
imaging (MRI) with gadolinium or positron emission 
tomography (PET)/CT with 2-[fluorine-18]-fluoro-2-
deoxyD-glucose (18F-FDG) (26). CT and MRI can accurately 
locate the lesion and its relationship with or invasion into 
adjacent tissues. Both are commonly used when planning 
en bloc resection of the lesion and surrounding structures. 
The sensitivity of a single preoperative imaging (US, CT or 
MIBI) has been reported to be ~80% but this increases up 
to 95% when the three procedures are used together (26). 
Thus, in a given patient with suspicion for PC combined 
preoperative imaging studies are recommended. The 
role of FDG-PET is still debated; of note, the lesions of 
osteitis fibrosa cystica, which can be present in patients 
with PC, are hypermetabolic and positive at FDG-PET 
and, therefore, could be misdiagnosed as bone metastasis 
(27). Preoperative fine-needle parathyroid biopsy is not 
recommended because it cannot distinguish a benign 
from a malignant lesion and has a risk of tumoral rupture 
and seeding (28).
Pathogenesis and histopathology
Pathogenesis
PC can arise in the context of the CDC73 related disorder 
(or HPT-JT syndrome and anecdotally in the context of 
MEN1 and MEN2A syndromes). Sporadic inactivation of 
CDC73 and other genetic factors are driving parathyroid 
cancers, but there are no data why these DNA variations 
would occur in these relatively oligo-dividing parathyroid 
cells, with a relatively low chance of replication errors 
and less environmental influences (including lifestyle) 
than seen in other tumor types (29). However, a history 
of radiation exposure has been reported in PC (30). 
Proliferation of parathyroid cells due to renal failure with 
secondary hyperparathyroidism might occasionally drive 
parathyroid tumorigenesis towards malignancy (31). An 
alternative explanation for which there is no formal proof 
is that in metabolically hyperactive cells increased reactive 
oxygen species might lead to subsequent DNA damage 
targeting crucial pathways in parathyroid homeostasis. As 
also postulated by Tomasetti and Vogelstein for cancers in 
general, possibly bad luck is another valid explanation for 
PC tumorigenesis (29).
Histopathology
The correct histopathological diagnosis of malignancy 
(WHO Classification of Tumours of Endocrine Organs, 
2017) is primarily based on two strict criteria, that 
is, ingrowth of tumor cells beyond the preexistent 
parathyroid capsule into surrounding tissues and the 
presence of lymphangio-invasiveness. The presence of 
atypical mitotic figures and fibrous septa may be helpful 
as they are often associated with malignancy. An example 
of PC is given in Fig. 2. Other criteria like nuclear atypia 
and the lack of uniformity of the cells are being more 
circumstantial. Additional immunohistochemical staining 
may help to support the diagnosis and the ones that are 
Figure 1
Ultrasound image of a parathyroid carcinoma. The tumor 
(arrows), located at the upper pole of the thyroid, shows a 
heterogeneous pattern, irregular shape and halo sign 
(longitudinal view) (from Cetani et al. JEI 2016, with 
permission (18)).
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used currently are Ki67, Galectin 3, protein gene product 
9.5 (PGP9.5) and parafibromin (encoded by CDC73) (32). 
Furthermore, loss of parafibromin expression and the 
finding of inactivating CDC73 DNA variants can be found 
in aggressively behaving parathyroid cancers (33, 34), and 
as such provide prognostic information.
At this moment, there are no well-established tissue 
biomarkers that can delineate parathyroid carcinoma 
(unequivocal carcinoma) from atypical adenomas 
(or equivocal carcinoma). For example, there is no 
evidence that recently described limited gene panels for 
PC (as outlined in the section titled 'Germline mutation 
testing') or larger commercial gene panels can be 
helpful to answer such diagnostic questions. Probably 
only finding CDC73 pathogenic variants would point 
to a more aggressive potential although only in cases 
with histological confirmation. Finding MEN1 variants 
would shift the odds to a more benign potential. 
Other biomarkers, such as microRNA profiles might be 
thought of.
Germline mutation testing
Testing for germline mutation of the CDC73 gene is 
strongly recommended in patients with apparently 
sporadic PC. The mutation detection yield ranges from 6 
to 38% according to the different studies (10, 21, 33, 35, 
36, 37, 38). The sample size, the selection bias and, not 
less important, the challenging of the histopathological 
diagnosis, could account for these differences. However, 
the latter is of utmost importance because it determines 
the prognosis of the patients. The majority of these 
mutations is widespread throughout the coding region, 
but most are located in exons 1, 2 and 7 (10, 21, 33, 35, 
36, 37, 38). Gross deletions within the gene have been 
identified in a few cases of patient with PC (37, 38, 39). 
Therefore, in CDC73-negative cases for point/small 
mutations, the research of CDC73 gross deletions should 
be considered.
Germline mutations in additional genes including 
PRUNE2, CCD1, ADCK1 and genes of PI3K/AKT/mTOR 
Figure 2
Histopathology: Parathyroid carcinoma in the context of CDC73-related disorder. Concerns index patient III.2 of family G described 
by van der Tuin et al. (Supplementary Fig. 1 and Supplementary Table 1 in the reference (38)). This male patient was diagnosed 
with PC at the age 45 years after he presented with primary hyperparathyroidism and a right-sided mass in the neck of 6 cm with 
lymph node metastases. The patient eventually died of this disease. Germ line CDC73 (HRPT2) analysis showed a large deletion of 
the q-arm of chromosome 1 including the complete CDC73 gene. In the upper part of the figure, a hematoxylin and eosin stained 
histological slide is presented. The tumour showed pleiomorphic parathyroid hormone positive staining cells with anisokaryosis 
and prominent nucleoli. Broad fibrous bands were between tumour cell islands. Occasionally mitoses were observed. The Ki-67 
index was focally around 5%. Lymph angio-invasiveness outside the tumour mass was seen. Parafibromin immunohistochemistry 
showed vague positive and focal complete lack of nuclear staining of tumour cell in comparison with internal reference cells. 
There was enhanced cytoplasmic staining of tumour cells. In the lower part of the figure somatic CDC73 (HRPT2) Sanger DNA-
sequencing results are depicted showing a forward reference sequence above the tumour sequence. This region was not well 
covered in a targeted CDC73 containing gene panel for next-generation sequencing that was also analysed. In the tumour as a 
second hit on the wild type allele a pathogenic CDC73 exon 1: c.91_92delinsGGAA, p.(Ser31Glyfs*7) gene variant was identified.
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pathways have been detected in patients with PC (40, 
41). Therefore, gene panel testing using next-generation 
sequencing should be considered because it would 
improve the genetic analysis.
In clinical practice, the genetic testing for germline 
mutations is helpful in the index case and, if positive, 
first-degree relatives of all patients with PC in order to
(i)   identify the germline mutation in a given patient 
with PC;
(ii)   identify asymptomatic family members carrying the 
mutation and thus requiring a clinical evaluation 
for early detection of the tumor and appropriate 
treatment;
(iii)   relieve the anxiety of developing the disease family 
members who do not carry the mutation;
(iv)   start the screening for HPT-JT-related tumors in the 
index case and healthy carriers. Indeed, patients with 
CDC73-related disorders might develop ossifying 
fibromas of the maxilla and/or mandible and uterine 
tumors and renal lesions.
Surgery of parathyroid carcinoma
Successful surgery depends on preoperative suspicion of 
PC and intraoperative recognition of malignant features, 
such as size (often >3 cm), firmness, grayish-white color 
and adherence/invasion to surrounding tissues. Local 
excision is not acceptable, the only way of ensuring cure 
is complete removal of the tumor while avoiding capsule 
rupture and including all surrounding tissues involved 
(en bloc resection) (22). Achieving microscopically 
disease-free margins improves disease-free survival (42). 
Prognosis is influenced by surgeon performance (43). If 
PC is suspected, surgery should thus be performed by an 
expert parathyroid surgeon in a large-volume center. If 
the patient has not undergone primary en bloc resection 
and histopathological confirmation of PC comes as a 
surprise, timely further expert parathyroid surgery must 
be considered. Surgery is first-line treatment also for 
recurrent disease and, in selected cases repeated operations 
in combination with other systemic treatments may 
improve the prognosis (44).
Systemic treatments
Most patients with inoperable PC ultimately succumb to 
severe hypercalcemia and kidney failure rather than tumour 
burden. The management of acute severe hypercalcemia 
includes intravenous saline infusion to restore fluid volume 
and increase urinary calcium excretion, and occasionally 
loop diuretics to enhance the calciuresis (16, 18, 45). 
However, such measures are of temporary success only, 
and other approaches (e.g. drugs such as cinacalcet) are 
required for longer-term success. Cinacalcet, a calcimimetic 
binding to the calcium-sensing receptor and thereby 
decreases PTH secretion, is a potent oral calcium-lowering 
agent. The starting dose is 30 mg twice daily, with dose 
adjustments every 2  weeks until calcium concentrations 
are acceptable (17). Nausea is a common side effect that 
may prevent the usage of higher doses. Cinacalcet can 
be combined with zoledronic acid (44), the most potent 
known bisphopshonate (4 mg i.v every 3–4 weeks) or, with 
denosumab, a monoclonal antibody that binds to RANKL 
(120 mg s.c monthly), especially in refractory cases and 
patients with impaired kidney function (46, 47). There are 
however, no evidence-based specific treatments. Anecdotal 
positive responses to adjuvant radiotherapy (10, 48, 49, 
50), PTH immunotherapy (51, 52) and alkylating agents 
as iv dacarbazine (53) and oral temozolomide have been 
reported (44).
Future networking, biobanking, future joint 
efforts for a deeper understanding of 
pathogenesis, to enable tailored treatments
It is of paramount importance to refer patients with 
suspicion of PC to tertiary care centers with skilled 
endocrine surgeons who are familiar with the treatment 
of this rare disease. It would be very desirable to set-up 
European prospective registries and biobanks to collect 
large number of patients with PC and bio-specimens 
(tissues, blood, serum, urine, etc). Such a project 
would ensure an adequate sample size to improve our 
understanding on not yet clear clinical preoperative, 
surgical and histological findings. One of the main 
goals would be to define preoperative biomarkers to 
differentiate between malignant lesions and the much 
more common benign counterpart, and subsequently 
a better understanding of the pathogenesis of PC. This 
would lead to better planning the initial surgical procedure 
as this greatly influences the prognosis of patients with PC 
and their management.
Extensive epidemiological data on the occurrence of 
PC have so far not been compiled from all countries in 
Europe and results on treatment outcomes have not been 
evaluated. Treatment options for recurrent PC are so far 
limited. Being a rare disease, the treatment of recurrent PC 
can benefit from the developments in personalized cancer 
care. These developments encompass the elucidation 
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of relatively rare but targetable DNA variations, gene 
amplifications and gene fusions across many cancer types 
(54, 55). For example, DNA alterations of the PIK3CA-
PTEN-mTOR-AKT pathway, gene amplifications (HER2, 
FGFR3 etc.) or gene fusions (involving ALK, ROS, RET, 
NTRK) are seen in different cancer types, although with 
different frequencies. Indeed, recent studies reported 
potentially targetable ROS1, TSC1, AKT1, MTOR, PTEN, 
PIK3CA, NF1, KDR, ERBB1, NTRK1, IDH1 and FGFR3 
DNA variants in PC in the presence or absence of CDC73 
mutations, with rationally matched targeted agents (41, 
56, 57). Single PC cases showed clinical benefit from 
tyrosine kinase inhibitors (56). In PC cases with high 
mutational loads or burdens, the applicability of different 
forms of immunotherapy (for example anti PD1 immune 
de-blockade therapy) might be envisioned. Although 
the median total mutational burden in PC is relatively 
low (1.7 mutations per megabase (m/Mb), about 20% 
demonstrated high mutational burden (>20 m/Mb)) (40, 
56). The latter translates into a higher neo-antigen load 
with a chance that abnormal tumor peptide fragments 
are presented on the tumor cell surface in the context 
of HLA and thereby leading to cytotoxic T-cell responses 
(58, 59). Repurposing existing drugs can be thought of as 
shown by the effectivity of temozolomide in an isolated 
PC case (44). As stated, there is a relatively high frequent 
inactivation of CDC73 in PC. The parafibromin protein 
encoded by CDC73 is part of the PAF1 complex involved 
in cell cycle regulation. It should be studied whether the 
latter would impose increased sensitivity to cell cycle 
inhibitors. Similarly cyclin D1 might be targeted as 
CCND1 is found to be amplified in PC cases, reviewed 
recently by Costa-Guda (60). In human cancers with 
P16 loss (encoded by CDKN2A), cell cycle inhibitors are 
given (CDK4/6 inhibitors) (61). To bring this field further, 
PC-specific comprehensive integrative molecular analysis 
(of the mutome, transcriptome, methylome, miRNAome, 
etc.) is lacking. So far, isolated relatively small series of 
PC have been studied by extensive genomic analysis 
including exome analysis (40, 41, 56, 62, 63). There are 
no well-characterized cell lines available to facilitate 
biological research. For this purpose, future networking 
is of utmost importance to improve research and the 
treatment possibilities in recurrent PC.
Chronic hypoparathyroidism in adults
Hypoparathyroidism (HypoPT) is a rare disease with an 
estimated prevalence of ~30 patients per 100,000 people 
(64). In adults, chronic HypoPT is most often secondary 
to neck surgery, having a surprisingly high prevalence of 
10–24/100.000 inhabitants (6, 64, 65). From a therapeutic 
aspect, HypoPT is the last endocrine deficiency syndrome 
not replaced by the lacking hormone in standard care (7, 
66). The indirect standard treatment or an un-physiologic 
substitution therapy might give challenges affecting 
quality of life (QoL) for the patients but also potential 
long-term complications (6, 67, 68, 69, 70, 71).
The diagnosis of hypoparathyroidism
HypoPT has been clearly defined in the guidelines on 
'Treatment of chronic hypoparathyroidism in adults' by 
ESE as ‘a disease with hypocalcaemia and inappropriately 
low parathyroid hormone (PTH) levels’ (7). A similar 
definition has been suggested by other expert groups 
(66, 72). Despite this general consensus, it seems that 
HypoPT is defined in many different ways in the scientific 
literature. In 2010, Mehanna et al. (73) published a review 
on papers reporting risk of postoperative hypocalcemia. 
Based on a systematic literature search, a total of 62 
papers were identified. The majority of the papers did not 
specifically define hypocalcemia and the papers reporting 
this used ten different definitions. By applying these 10 
different definitions to the same cohort of 202 thyroid 
surgery cases at a single institution, it was found that that 
the incidence of hypocalcemia varied widely (0–46%) 
depending on the definition used. Most recently, another 
systematic literature review has been published on papers 
reporting on risk of permanent postsurgical HypoPT 
between 2010 and 2011 (74). The review identified 89 
articles using 20 different definitions and reported an 
incidence varying from 0.0–20.2%. None of the definitions 
used were in accordance with the generally accepted 
definition. Accordingly, there is a need for standardization 
of the definitions used for reporting hypocalcemia rates. 
Otherwise, patients are not diagnosed in a proper manner 
and thereby may not receive appropriate treatment.
HypoPT is a complicated disease
It has become more and more clear that HypoPT is more 
than just a matter of supplying calcium and activated 
vitamin D. HypoPT is a complicated disease with deficiency 
of two hormones, PTH and 1,25 (OH)2Vit D (64) (Fig. 3). 
In addition to hypocalcemia, HypoPT is associated with 
other biochemical disturbances, such as hypercalciuria 
and hyperphosphatemia, as well as an impaired quality 
of life and an increased risk of co-morbidities, including 
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renal stones/impairment, neuropsychiatric diseases and 
infections.
Renal stones
Huge variations in the prevalence of renal stones have 
been reported, varying from 1.9–40%. As shown in 
Table 1, the presence of renal stones has been assessed 
by different methods, which at least in part may explain 
this variability. Only few studies have compared the risk 
of renal stones in HypoPT with the general population. 
A recent cross-sectional study from Italy reported renal 
calcifications in 30% of patients with HypoPT, which 
was eight-fold higher than that in an age- and gender-
matched control group (odds ratio (OR) 8.2; 95% 
confidence interval (95% CI) 3.4–19.9) (75). On the 
contrary, a Danish controlled cohort study reported 
the risk of renal stones to be ‘only’ four-fold increased 
(OR 4.0; 95% CI, 1.6–9.9), compared to the general 
population (65). In the Italian study, renal calcifications 
were assessed by ultrasound examinations and most 
patients were asymptomatic, whereas hospital discharge 
codes were used in the Danish study and most patients 
were symptomatic. Accordingly, HypoPT seems to be 
associated with a four- and eight-fold increased risk of 
symptomatic and asymptomatic renal calcifications.
Hypercalciuria
Idiopathic hypercalciuria occurs with a prevalence of 
5–10% in the general population and is associated with an 
increased risk of renal stones (76). Due to the lack of PTH, 
renal calcium excretion is increased in HypoPT (Fig. 3) and 
a prevalence of hypercalciuria as high as 25–50% has been 
reported (75, 77, 78). Although no good data are available 
on associations between renal calcium excretion and the 
risk of renal stones in HypoPT, it seems likely to consider 
hypercalciuria as a causative factor for the increased risk 
of renal stones in HypoPT.
In general, it is recommended to aim at serum 
calcium levels in the low-normal range when treating 
HypoPT (7). The reason is the well-known association 
between serum and urinary calcium that is, renal 
calcium excretion increases with increased serum 
calcium levels (79). Furthermore, thiazide diuretics 
have been shown to decrease urinary calcium in 
HypoPT and may increase serum calcium levels, thereby 
lowering needs for calcium supplements and activated 
vitamin D analogues (80). In idiopathic hypercalciuria, 
thiazides have been shown to reduce the risk of renal 
stones and it seems likely that thiazides may exert a 
similar effect in HypoPT (81). However, the precise 
indication for use of thiazides in HypoPT needs further 
evaluations.
Figure 3
Overall calcium homeostasis in chronic hypoparathyroidism. 
In chronic hypoparathyroidism in adults, overall calcium 
metabolism is reflected by the lack of PTH. Bone turnover is 
markedly decreased as is the net release of calcium from the 
stores in bone. Levels of active vitamin D (1.25-(OH)2–Vit D) are 
low due to lack of the PTH driven 1-α-hydroxylase followed by 
decreased intestinal absorption of calcium. The renal tubular 
reabsorption of calcium is decreased. Moreover, phosphate 
levels are high – not illustrated in the figure.
Table 1 Prevalence of renal calcifications in hypoparathyroidism as reported in studies from different countries.
Country No of patients Type of examinations Prevalence of renal calcifications (%)
Underbjerg 2013 (64) Denmark 688 ICD codes 1.9 
Arlt 2002 (66) USA 25 Ultrasound 8 
Rubin 2008 (152) USA 33 ? 15 
Hadker 2014 (153) USA 374 Self-reported 25 
Meola 2018 (74) Italy 82 Ultrasound 30
Lopes 2016 (154) Brazil 40 Ultrasound 25
Mitchell 2012 (77) USA 54 Renal imaging 31
Winer 2003 (155) USA 27 CT scans 40
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Sodium restriction
Salt restriction has been associated with decreased 24-h 
renal calcium excretion in subjects with hypercalciuria, 
as a high sodium intake increases calcium excretion 
which also may lower serum calcium levels in HypoPT 
(82). Some patients with HypoPT are prone to develop 
sudden episodes of hypocalcemia without any obvious 
explanation. It should be further investigated whether 
an intermittent high intake of sodium may contribute to 
fluctuations in serum calcium levels in HypoPT.
Biochemistry and risk of complications
In a recent study, risk of complications to HypoPT 
has been associated with the biochemical profile (83). 
Accordingly, relatively high plasma phosphate levels and/
or a high calcium-phosphate product was associated with 
an increased mortality as well as an increased risk of renal 
diseases and infections. Low levels of ionized calcium were 
associated with an increased risk of cardiovascular diseases 
and episodes of hypercalcemia were associated with 
increased mortality and risk of infections, cardiovascular- 
and renal-diseases, beyond kidney calcifications. Whether 
improving the biochemical control can lower risk of 
complications of HypoPT needs to be investigated in 
further prospective studies.
Are our patients well treated?
A comparison of different treatment forms in HypoPT 
on biochemical parameters or complications are not 
available to date. Treatment seems rather to depend on the 
availability of active vitamin D compounds in different 
countries. In a Danish study, alfacalcidol was exclusively 
used (84), in the USA calcitriol (78), in Norway both 
active compounds were given (6), whereas in Germany 
in addition to calcitriol and alfacalcidol, the long-acting 
dihydrotachysterol is available (67). Furthermore, the 
use of supplemental calcium differs geographically, 
being highest in the USA (78), whereas higher doses of 
active vitamin D are used in Europe (6, 67, 84, 85). The 
European guidelines and international recommendations 
(7, 66) propose an standardized treatment with the aim 
of reducing symptoms and complications by control of 
multiple biochemical parameters beyond serum calcium, 
including serum phosphate, calcium–phosphate product, 
magnesium and urinary calcium excretion (7). A cross-
sectional study from Italy indicated that only 34.1% 
treated with conventional therapy (calcium and calcitriol) 
met the biochemical targets defined by the ESE guidelines 
(75). The best treatment option to reach these goals is still 
to be established.
Quality of life
Optimal control of HypoPT should not be restricted 
simply to restoring biochemical markers. In a number of 
chronic diseases, quality of life (QoL) of the patients is 
supposed to be a hallmark of therapy (86, 87, 88) and is 
regarded as essential also for HypoPT patients by the ESE 
evidence-based guideline (7). Several instruments for the 
characterization of QoL in HypoPT patients were used, 
including the Short Form-36 (SF-36), the Hospital Anxiety 
and Depression Scale (HADS) and the WHO-5 Well-
Being Index survey (WHO-5) (6, 68, 70, 71, 85). These 
different questionnaires revealed large deviations from 
the norms observed in the general population (6, 68, 85). 
However, when involving patient control groups instead 
of population norms studies were less encouraging (67, 
69). Also treatment studies using rhPTH[1–84] using the 
generic SF-36 tool proved unable to detect any difference 
in the quality of life when compared to a control 
group treated with placebo (67, 69, 71). Symptoms of 
hypoparathyroidism are diverse and frequently hard to 
classify (69, 89). The knowledge and characterization of 
symptoms is thus essential to establish and validate tools 
that help to define optimal disease control (7, 90, 91, 92). 
Hence, the importance of hypoparathyroidism-specific 
instruments to assess symptoms has been regarded lately 
as crucial to improve our understanding of the nature 
and the degree of impairments to QoL (71, 90). These 
should also take into account patients’ compliance with 
treatment which may be influenced by drug cost and 
a multiple tablet burden. Findings from a 13-Country 
patient survey highlight the substantial burden of illness 
that negatively impacts health-related QoL (HRQoL) and 
health status in patients with chronic HypoPT. The degree 
of HRQoL reduction reflected the magnitude of symptom 
severity reported by patients; the greater the symptom 
severity level, the lower the HRQoL (93). In addition, 
a disease characteristic questionnaire was developed 
in comparison with control groups (94). With these 
instruments, individual differences, and their relationship 
to biochemical variables (if any) and treatment modalities 
need to be investigated in the future to identify the best 
treatment option for the well-being of our patients.
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Further perspectives and unmet needs in Chronic 
HypoPT in adults
There has been an increasing awareness on chronic 
HypoPT in recent years, primarily driven by epidemiologic 
and systematic clinical studies focusing on QoL, morbidity 
and co-morbidities, as indicated in the newly published 
treatment guidelines (7, 66). Most patients do develop 
chronic HypoPT following neck surgery, and there is a 
need for a better understanding of the pathophysiology 
of post-thyroidectomy parathyroid failure (95, 96). As 
most of the current knowledge is based on cross-sectional 
or short-term intervention studies, prospective studies on 
modern treatment modalities are warranted and needed. 
Such studies should be based on strict diagnostic criteria 
and include prospectively defined endpoint also taking 
comorbidities and late complications into account. PTH 
replacement therapy has been marketed as adjunctive 
treatment of adult patients with chronic HypoPT, 
who cannot be adequately controlled with standard 
therapy alone. Intuitively, substitution with the missing 
hormone seems an attractive approach. However, data 
from randomized clinical trials (RCT) have so far only 
documented that PTH therapy lowers serum phosphate 
levels and doses of calcium supplements and activated 
vitamin D needed to maintain normocalcemia (77, 97). 
Neither an improved QoL, nor lowering of urine calcium 
has been documented in RCTs. Currently, only treatment 
regimens using once-a-day injections are available. Such 
regimens cause a sharp rise in plasma PTH levels. However, 
due to a short plasma-half life, PTH is only present in 
the circulation for 8–12 h after an injection. Data from 
studies using twice-a-day injections as well as continuous 
infusion by pump delivery have been publish showing a 
plasma profile more similar to normal physiology (98). 
Further studies are needed to elucidate the importance of 
different PTH treatment regimens on its effects.
More information on transition from childhood 
to adult care, on pregnancy and the early puerperium 
is essential. QoL seems to be very low in patients 
with chronic HypoPT, but so far mostly based on 
generic questionnaires, disease specific tools should be 
implemented, and also studies including the burden of 
symptoms as perceived from the patients perspective. The 
prospective and randomized clinical trials with QoL as 
an endpoint have so far not given a clear answer on the 
benefit of substitution with PTH as once-a-day injections 
compared with standard treatment (69, 99), a further 
unmet need at all levels. The future development of new 
technology for instant calcium determination which can 
be used by the patients themselves would not only support 
the intended studies but also help to better understand 
the significance of value control by the individual patient 
on their burden of symptoms.
Primary hyperparathyroidism
PHPT has become a common disease in developed 
countries, where the diagnosis often is made by chance 
in patients without specific symptoms, whereas the 
severe classical findings of PHPT most often are diagnosed 
in developing areas (100), potentially reflecting a real 
under diagnosing of the disease in these countries. With 
the change in clinical presentation, the question of 
management of asymptomatic patients (mild PHPT) has 
been discussed, often based on sparse evidence (101). 
Given PHPT as a common disease, most often in peri- 
and postmenopausal women (1, 2) with a prevalence of 
2–5% in Scandinavian women, and most data derived 
from observational and case control studies, we will here 
concentrate on some areas of the disease spectrum that 
should be focused on in the immediate time to come.
Qualitative aspects of bone tissue in PHPT
Due to the high PTH levels (Fig.  4), bone turnover is 
increased in PHPT leading to an, in principle reversible 
bone loss based on the coupling principle and an 
enlargement of the remodeling space (102). Thereby, 
bone mass should be normalized by successful surgery 
and fracture frequency also be controlled. Based on large 
cohort studies, the fracture prevalence seemed to decrease 
compared to the pre-surgery situation in PHPT, but it was 
still increased compared the background population (103, 
104). These data refer primarily to appendicular fractures, 
as vertebral fractures classically are underdiagnosed (101). 
Studies based on histomorphometry of iliac bone biopsies 
have indicated a preservation of trabecular bone, but also 
a trabecularization of the endosteal envelope leading to 
a thinning of the cortical shell (105, 106, 107, 108). In 
trabecular bone, the increased turnover is followed by an 
increase in the activation frequency, a shortening of the 
bone resorption period and of particular interest, a decrease 
in the resorption depth. The bone formation phase is also 
decreased, and the overall bone balance has been found 
to be even positive (reviewed in (102)). These findings 
are in accordance with an increased risk of peripheral 
fractures, but also indicating an unaltered or even reduced 
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risk of vertebral fractures, also in agreement with findings 
by DXA (102). Conversely, recent studies have found a 
high prevalence of vertebral fractures in patients of both 
sexes in both younger and older patients with PHPT, and 
even in patients with mild PHPT (109, 110). In the recent 
Danish study, the overall prevalence of vertebral fractures 
was around 22% for all age groups, and of interest higher 
in men compared with women in younger patients less 
than 60 years. Most of the fractures were mild to moderate 
and only 28.7% had severe fractures by the method of 
Genant (111, 112). When compared to patients with 
postmenopausal osteoporosis, patients with PHPT seemed 
to fracture at a higher BMD level (112). These findings 
are supported by microarchitectural analyses by HRpQCT 
imaging, showing decreased trabecular and cortical bone 
microstructure in active PHPT (113, 114). Randomized 
controlled studies have indicated a treatment effect of 
surgery on bone mass by DXA in the 5-year perspective, 
but not for cortical bone as seen in the proximal forearm 
(115, 116), of importance for the risk of low energy fracture 
(116). Microarchitectural analyses have supported these 
data, showing an improvement in bone mass indices in 
both trabecular and cortical bone by HRpQCT, starting 
already 6 month after surgical cure of PHPT in both sexes, 
and continuing up to 2  years following surgery (117). 
These improvements were attributed to a decrease in bone 
turnover and leading to a presumably increase in bone 
strength in both bone compartments, as demonstrated 
indirectly by finate element analyses (117).
Is the cardiovascular burden increased in mild 
disease and potential reversible?
Based on epidemiologic studies, PTH reflects cardiovascular 
(CV) risk in elderly men, even in the normal PTH 
range (118). PHPT is associated with a state of insulin 
resistance (119) and PTH is directly positively correlated 
to Left Ventricular Mass Index in PHPT (120). PHPT is 
also related to arterial hypertension, but reversibility by 
surgical treatment has not been demonstrated (116, 121, 
122). CV-mortality is increased in PTHP and a threshold 
effect for calcium levels has been discussed based on case-
control studies (104, 123), below which an increased CV 
risk could not be demonstrated. A recent meta-analysis 
on the effect on echocardiography measures of surgical 
treatment in PHPT could not demonstrate signs of 
reversibility neither in observational nor randomized 
studies (124). The findings are in accordance with 
biochemical markers of insulin resistance and CV-risk 
based on 2 and 5-year data from the randomized 
Scandinavian study of PHPT (121, 125). Even though a 
positive treatment effect of surgery on vitamin D levels 
(25(OH)D) was demonstrated, no effect was seen on body 
composition and various measures of insulin resistance 
5 years following randomization (116, 125).
The increased CV-risk in PHPT is influenced by 
traditional CV-risk factors and these might therefore 
partly explain the lack of reversibility of CV-endpoints by 
surgical treatment in PHPT (122). At the third international 
workshop on management of mild (asymptomatic) PHPT, 
it was stated that demonstration of CV-risk reversibility 
by surgery could change overall recommendations (126). 
Even though data from long term randomized studies have 
now emerged, the data have not indicated a change in 
the recommendations for management based on CV-risk. 
Thus, increased CV-risk is at present not considered to be 
an indication for parathyroidectomy in PHPT (11).
Will patients with mild disease improve QoL 
with treatment?
Patients with mild or asymptomatic PHPT have decreased 
QoL based on generic QoL questionnaires (2, 127, 128, 
129, 130). Numerous observational studies including the 
most recent have indicated a positive treatment effect of 
surgery on QoL (131, 132, 133). Randomized controlled 
studies have shown ambiguous results (128, 129, 130), 
Figure 4
Overall calcium homeostasis in primary hyperparathyroidism. 
Due to a set-point error in PHPT, circulating PTH levels are 
inappropriately increased leading to a new steady state with 
increased PTH and calcium levels. Bone turnover, the renal 
tubular reabsorption of calcium, the activation of vitamin D 
followed by calcium absorption from the gut are all increased 
leading to the new steady state, which in principle is able to be 
regulated – just at a higher level.
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demonstrating no significant effect of surgical treatment 
on QoL in patients not fulfilling the surgical criteria for 
PHPT, as summarized in a recent meta-analysis (134). A 
disease specific questionnaire (PHPQoL) has recently been 
developed (135). The tool seems reliable with good internal 
consistency and sensitive to changes over time. It was 
also demonstrated that PHPQoL correlated significantly 
with generic, traditional questionnaires and the tool was 
sensitive to the degree calcium related symptoms (135). 
So far the experience with PHPQoL tool is limited, but a 
recent observational study demonstrated an improvement 
in PHPQoL following parathyroidectomy, independent of 
calcium levels (136). PHPQoL has so far not been tested in 
randomized, controlled studies.
Due to ambiguous results from controlled studies and 
few data based on disease specific questionnaires, low QoL 
alone has not been an indication for surgical treatment of 
PHPT (11).
Normocalcemic PHPT: How can the diagnosis 
be secured?
Normocalcemic PHPT is defined by the finding of plasma 
PTH consistently (at least three determinations) elevated 
associated with normal total (albumin-corrected) and 
ionized calcium, after the exclusion of any other cause of 
secondary hyperparathyroidism:
(i)   serum 25(OH)D <75 nmol/l,
(ii)  eGFR <60 ml/min per 1.73 m2,
(iii) 24-h urinary calcium >8.75 mmol (350 mg),
(iv)  gastrointestinal disorders associated with calcium 
and/or vitamin D malabsorption, and
(v)   medications that could alter calcium homeostasis, 
including lithium, thiazide- and loop-diuretics, 
bisphosphonates or Denosumab (137).
These patients should be distinguished from patients 
with classical hypercalcemic hyperparathyroidism, who 
occasionally may have normal total and ionized serum 
calcium. We should also remind that about 10-15% of 
patients with classic PHPT may have albumin-corrected 
serum calcium in the normal range, but elevated ionized 
calcium (138).
Several critical issues should be considered to secure 
the diagnosis of normocalcemic PHPT. The first problem 
is the definition of normocalcemia using the range 
of serum calcium in the normal population (usually 
2.15 – 2.55 mmol/l (8.6-10.2 mg/dl)). The individual 
variation in serum calcium is four times narrower that 
the inter individual variability, and for ionized calcium 
the variability is in the order of 0.02 mmol/liter (139). 
Thus, to be certain that the measured serum calcium 
is normal, we should know the range of variability of 
each individual subject. Therefore, facing a subject with 
the biochemical signature of normocalcemic PHPT, 
particularly when ionized calcium is in the upper normal 
range, we cannot exclude that the correct diagnosis could 
be classical PHPT, which is much more common than 
normocalcemic PHPT. Before making a definite diagnosis 
of normocalcemic PHPT, the patient must be replete for 
calcium and vitamin D intake for several weeks before 
the diagnostic sample. A second problem is the exclusion 
of secondary hyperparathyroidism, particularly when 
ionized calcium is in the lower normal range, on the 
basis of the cut-off values identified for serum 25(OH)
D, eGFR and 24-h urinary calcium. The relationship 
between plasma PTH and each of these variables differs 
in different individuals. Therefore in the same individual, 
the coexistence of increased plasma PTH associated with 
values of serum 25(OH)D and eGFR above, and 24-h 
urinary calcium below the relative cut-offs, might be 
compatible with a form secondary hyperparathyroidism. 
A third problem is to exclude subtle gastrointestinal 
disorders that may cause calcium malabsorption. A 
fourth problem emerged from data from the Dallas Heart 
study, in which, after the exclusion of subjects with eGFR 
<60 ml/min and thiazide diuretics and lithium use, the 
prevalence of normocalcemic PHPT dropped from 3.1% 
to 0.6%, when many of these subjects were reinvestigate 
6  years later (137). Finally, a low calcium intake could 
also contribute to increasing plasma PTH. In conclusion 
cautions should be recommended before concluding that 
a biochemical signature translates into a disease entity. 
Nonetheless, these subjects should be followed because 
some of them may develop the classic hypercalcemic 
form of PHPT (140).
Risk factors for nephrolithiasis and value of the 
‘biochemical urinary stone risk profile’
Recent studies have shown an increasing prevalence 
(7-35%) of silent kidney stones in patients with PHPT (112, 
141). Hypercalciuria is a risk factor for nephrolithiasis and 
a higher mean urinary calcium excretion has been shown 
in patients with PHPT and kidney stones compared with 
those without (112). On the other hand, nephrolithiasis 
may occur in the absence of hypercalciuria, suggesting 
that factor(s) other than hypercalciuria may contribute 
to stone formation. In this regard, the latest guidelines 
for the management of asymptomatic PHPT recommend 
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a more complete biochemical urinary stone risk profile 
evaluation, when 24-hour urinary calcium excretion is 
above 10 mmol (400 mg) (11). The rational for choosing 
this cut-off value is unclear and does not consider that the 
upper limit of normal urinary calcium excretion differs 
between men and women (7.5 mmol vs 6.25 mmol (300 mg 
vs 250 mg daily)). Tay et al. (142) recently reported that only 
31.6% of patients with asymptomatic PHPT and occult 
nephrolithiasis had U-Ca >10 mmol/24 h (400 mg/24 h). 
Similarly, we found urinary calcium above this cut-off in 
18 of 38 (47.4%) patients with asymptomatic PHPT and 
silent nephrolithiasis (unpublished data), confirming a 
poor sensitivity of this cut-off. Therefore, the question 
arises, whether other cut-off values could be more 
appropriate. Some, but not all, studies in mixed cohorts 
of symptomatic and asymptomatic PHPT have shown 
that high 24 h urinary oxalate and low citrate excretion 
are associated with nephrolithiasis (143). Further studies 
with a more complete assessment of urinary parameters 
that might be involved in stone risk formation in patients 
with asymptomatic PHPT are warranted.
Why are International guidelines not followed 
as expected?
Cohort studies as well as retrospective reviews of group’s 
records have shown that parathyroid surgery was performed 
in almost half of patients with symptomatic PHPT, in 
30-40% of those with asymptomatic PHPT who met at 
least one criterion for surgery, and in about one quarter of 
patients with asymptomatic PHPT who did not meet any 
criterion for surgery (144, 145, 146). A prospective study 
carried out in Italian tertiary referral centers in patients 
with newly diagnosed PHPT confirms that international 
guidelines are not obeyed over a follow-up period of 
one year after diagnosis. Indeed, parathyroidectomy was 
performed in 55.1% of patients with symptomatic PHPT 
and 53.7% of those with asymptomatic PHPT with at least 
one criterion for surgery. In both subgroups surveillance 
was advised when parathyroid imaging studies were 
negative. Parathyroidectomy was also performed in 25.7% 
of patients with asymptomatic PHPT and no surgical 
criteria, especially in those with positive parathyroid 
imaging studies (75%) (147). Therefore, in view of 
the well-established selective approach to parathyroid 
surgery (148), imaging studies could be considered in 
the therapeutic decision-making process in patients with 
asymptomatic PHPT, as suggested by some guidelines 
(149, 150).
Further perspectives and areas of uncertainty
Although bone as target tissue has been a matter of clinical 
and scientific interest for decades, the biomechanical 
properties of bone in PHPT is still a matter of uncertainty 
and debate. The most recent studies have indicated 
increased risk of low energy fractures even in mild PHPT, 
but also that patients with PHPT might fracture at a higher 
BMD level than expected and compared with patients 
with postmenopausal osteoporosis (110). The continuous 
loss of bone mass in non-operated patients calls for 
consideration of a more active approach towards fracture 
protection, being surgery or antiresorptive therapy (115, 
116), than recommended by the most recent international 
workshop (11). Another question arise when to start 
protective bone active treatment even before considering 
surgery both in classical or mild PHPT.
Several international guidelines and consensus 
reports have been published on the management of PHPT, 
and it is worrisome that the recommendations often not 
are followed. Recent long term data have emerged from 
randomized studies of mild PHPT without significantly 
demonstrating a treatment effect by surgery on CV-risk, 
presumable because of the importance of other CV-risk 
factors. Thus, at present the proposed threshold for 
calcium levels in PHPT given by epidemiologic studies has 
not been challenged. Most probably, the increased CV-risk 
is a combination of traditional risk factors for CV disease, 
and as well the increased calcium as PTH levels (151).
QoL is another area of controversy, as patients with 
PHPT have decreased scores by generic QoL tools and 
disease specific questionnaires only recently have been 
developed (135). So far, no benefit of parathyroidectomy 
on QoL from randomized studies has been demonstrated, 
and data from disease specific questionnaires are 
warranted.
Discussions and conclusions
The presentations and discussions from the first PARAT 
workshop held in Santpoort, The Netherlands in 
September 2018 are described in the present review, 
focusing on parathyroid disorders from an organ 
perspective with emphasis on unmet needs of importance 
for modern patient care.
Whereas benign parathyroid adenomas and 
hyperplasia are common in the clinic, PC are rarely seen 
and do call for special attention and transdisciplinary 
collaboration, the parathyroid surgeon and pathologist 
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having central roles. The understanding of the 
pathogenesis and natural history of PC is virtually 
unknown. Due to the rareness, no center can claim high 
experience on PC, and there is a need for central registries 
at different levels, for example through the European 
Reference Network on Rare Endocrine Conditions (ENDO-
ERN). From the perspective of the PARAT project, such a 
registry should have priority, but it is equally important 
to join forces to increase experience and knowledge, and 
moreover to avoid parallel registries. Lessons should be 
learned for improving preoperative diagnosis, but at the 
moment no reliable biomarker for PC has been developed 
or validated. A multinational registry could be a way 
forward, also giving possibilities for second opinion at 
the histopathological level, and for long-term follow-up 
of patients.
There is an international need for stringent 
diagnosing of chronic HypoPT in adults, and we suggest 
following the ESE definition of low calcium levels with low 
or inappropriate low levels of PTH (7), where the chronic 
state refers to 6-month duration, but 12  months could 
be considered to allow recovery (96). There is a need for 
a better understanding of the role of in situ parathyroid 
gland preservation in the prevention of HypoPT 
following surgery and to gain knowledge on the potential 
parathyroid reserve (95, 152). The burden of HypoPT is 
high for the patient with impairment in QoL and cognitive 
properties, often with fluctuations within short time. 
There is a need for better understanding of the relation 
between biomarkers of the disease (calcium levels) and 
intellectual function, but also to establish the importance 
of the lacking hormone (PTH) in target tissues. The 
optimal individual target of serum calcium concentration 
to be reached with therapy (within the low-normal range) 
may be un-physiologic and cause symptoms by some, as 
the individual calcium level normally varies little within a 
narrow range. Preoperative serum calcium concentration 
could guide the management of patients with post-
surgical HypoPt. Most patients with chronic HypoPT are 
females and in fertile age raising questions about optimal 
guidance during pregnancy and puerperium.
PHPT is a very common disease, especially in 
postmenopausal women (101). At present, we know little 
about the natural course of the disease in the modern clinic, 
and again it is virtually unknown whether morbidity and 
long-term outcome is related to the high calcium or PTH 
level or both (151). Cardiovascular morbidity is increased 
in PHPT, but potential reversibility by surgery is still a 
matter of debate and an issue for further research (122). 
Observation without intervention has been advocated for 
decades, but safely for how long time still remains to be 
answered. The natural history of fractures in PHPT is also 
controversial and need to be covered (112) in prospective 
studies. QoL is another controversial area in PHPT, where 
the recent developed disease specific questionnaire might 
be a step forward for a better understanding of the burden 
of the disease (135). Several international consensus 
statements on the management of PHPT have been 
published. With the accumulation of recent knowledge, 
a systematic and strictly evidence based clinical guideline 
should be considered.
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